Inovio Pharmaceuticals, Inc. (INO) PT Set at $13.00 by HC Wainwright
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a $13.00 price objective by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 94.61% from the stock’s previous close.
Several other equities analysts have also recently weighed in on INO. Maxim Group set a $12.00 price objective on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Citigroup Inc. began coverage on shares of Inovio Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $10.00 price objective on the stock. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. BidaskClub cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Aegis reiterated a “buy” rating and set a $14.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $19.98.
Shares of Inovio Pharmaceuticals (INO) opened at 6.68 on Friday. Inovio Pharmaceuticals has a 12-month low of $5.28 and a 12-month high of $9.86. The stock’s 50 day moving average price is $6.01 and its 200 day moving average price is $6.63. The firm’s market cap is $602.72 million.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The company had revenue of $20.41 million for the quarter, compared to analysts’ expectations of $16.29 million. During the same quarter in the prior year, the company earned ($0.26) earnings per share. The firm’s revenue was up 229.2% on a year-over-year basis. On average, equities research analysts predict that Inovio Pharmaceuticals will post ($0.92) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Inovio Pharmaceuticals, Inc. (INO) PT Set at $13.00 by HC Wainwright” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/06/inovio-pharmaceuticals-inc-ino-pt-set-at-13-00-by-hc-wainwright.html.
Several institutional investors have recently bought and sold shares of INO. Wasatch Advisors Inc. grew its holdings in shares of Inovio Pharmaceuticals by 43.6% during the 2nd quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock valued at $20,469,000 after acquiring an additional 793,306 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Inovio Pharmaceuticals by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock valued at $20,510,000 after acquiring an additional 226,861 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new position in shares of Inovio Pharmaceuticals during the 2nd quarter valued at $1,411,000. GSA Capital Partners LLP purchased a new position in shares of Inovio Pharmaceuticals during the 2nd quarter valued at $1,035,000. Finally, Virtu KCG Holdings LLC purchased a new position in shares of Inovio Pharmaceuticals during the 2nd quarter valued at $556,000. Institutional investors and hedge funds own 24.83% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.